1. Home
  2. ALT vs AMBC Comparison

ALT vs AMBC Comparison

Compare ALT & AMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • AMBC
  • Stock Information
  • Founded
  • ALT 1997
  • AMBC 1971
  • Country
  • ALT United States
  • AMBC United States
  • Employees
  • ALT N/A
  • AMBC N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • AMBC Property-Casualty Insurers
  • Sector
  • ALT Health Care
  • AMBC Finance
  • Exchange
  • ALT Nasdaq
  • AMBC Nasdaq
  • Market Cap
  • ALT 397.4M
  • AMBC 411.3M
  • IPO Year
  • ALT N/A
  • AMBC 1991
  • Fundamental
  • Price
  • ALT $4.16
  • AMBC $7.27
  • Analyst Decision
  • ALT Strong Buy
  • AMBC Strong Buy
  • Analyst Count
  • ALT 6
  • AMBC 2
  • Target Price
  • ALT $18.20
  • AMBC $12.50
  • AVG Volume (30 Days)
  • ALT 11.4M
  • AMBC 912.6K
  • Earning Date
  • ALT 08-07-2025
  • AMBC 08-04-2025
  • Dividend Yield
  • ALT N/A
  • AMBC N/A
  • EPS Growth
  • ALT N/A
  • AMBC N/A
  • EPS
  • ALT N/A
  • AMBC N/A
  • Revenue
  • ALT $20,000.00
  • AMBC $253,912,000.00
  • Revenue This Year
  • ALT N/A
  • AMBC N/A
  • Revenue Next Year
  • ALT $1,557,547.90
  • AMBC $17.41
  • P/E Ratio
  • ALT N/A
  • AMBC N/A
  • Revenue Growth
  • ALT N/A
  • AMBC 125.08
  • 52 Week Low
  • ALT $2.90
  • AMBC $5.99
  • 52 Week High
  • ALT $11.16
  • AMBC $13.64
  • Technical
  • Relative Strength Index (RSI)
  • ALT 40.54
  • AMBC 49.50
  • Support Level
  • ALT $4.07
  • AMBC $6.87
  • Resistance Level
  • ALT $4.79
  • AMBC $8.07
  • Average True Range (ATR)
  • ALT 0.45
  • AMBC 0.29
  • MACD
  • ALT -0.10
  • AMBC 0.03
  • Stochastic Oscillator
  • ALT 28.16
  • AMBC 28.69

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About AMBC Ambac Financial Group Inc.

Ambac Financial Group Inc is a financial services holding company. It operates in two principal businesses segments: Insurance Distribution and Specialty Property & Casualty Insurance. Insurance Distribution segment includes Managing General Agents, Underwriters and other appointed and delegated underwriting businesses (collectively MGAs or MGA/Us), an insurance broker, and other distribution and underwriting businesses. Specialty Property & Casualty Insurance includes five carriers (collectively, Everspan). Key revenue is generated from Insurance Distribution.

Share on Social Networks: